Strata Critical Medical (SRTA) Common Equity (2019 - 2026)

Strata Critical Medical (SRTA) has 8 years of Common Equity data on file, last reported at $285.7 million in Q1 2026.

• Common Equity for Q1 2026 came in at $285.7 million, up 30.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $285.7 million (up 30.04% YoY), and the FY2025 annual result was $279.1 million, up 25.74% from the prior year.
• Common Equity rose to $285.7 million in Q1 2026 per SRTA's latest filing, from $279.1 million in the prior quarter.
• Over five years, Common Equity peaked at $292.3 million in Q2 2022 and troughed at $219.7 million in Q1 2025.
• A 5-year average of $257.1 million and a median of $262.9 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity surged 3557.35% in 2022, then decreased 14.64% in 2023.
• A 5-year view of Common Equity shows it stood at $274.5 million in 2022, then declined by 14.64% to $234.3 million in 2023, then declined by 5.28% to $221.9 million in 2024, then gained by 25.74% to $279.1 million in 2025, then advanced by 2.39% to $285.7 million in 2026.
• Business Quant data shows SRTA's Common Equity at $285.7 million in Q1 2026, $279.1 million in Q4 2025, and $283.0 million in Q3 2025.